MAR 23, 2019 7:37 PM PDT

Bisphosphonates increasingly prescribed to the women most likely to benefit

WRITTEN BY: Nouran Amin

Recently, there has been a trend in the age of women who have been prescribed bisphosphonates (BPs) for the treatment osteoporosis and the prevention of fracture. Now, a recent study has investigated the characteristics of women who were placed on BP therapy changed over a recent 12-year period.

"Bisphosphonate drugs have been first-line therapy for osteoporosis and fracture prevention for more than 20 years; however, osteoporosis care has changed over the past decade. Instead of treating younger, healthier women at low risk for fracture, the medical community now focuses on treating older women and those with bone density and other factors that indicate high risk for future fracture," said senior study author Joan Lo, M.D., of Kaiser Permanente Northern California Division of Research in Oakland, Calif.

According to a study funded by the National Institute on Aging (NIA), women who were placed on BP treatment, the percentage with osteopenia declined while the percentage with osteoporosis at the time of starting treatment rose. The study included 28,495 female participants ranging from ages 50 to 79 years, who were placed oral BP therapy between 2002 and 2013 and underwent a bone mineral density (BMD) test within the past two years. The participants were also selected to not have any fracture history (except for head, fingers, or toes), and no indications of advanced kidney disease or metastatic cancer.

"These findings reflect the success of regional initiatives targeting these potent therapies to those who will benefit the most. In response to national guidelines and quality metrics introduced in 2008, we are doing a better job of giving more appropriate drug treatment to women who are most likely to benefit while avoiding excess treatment of women at low risk for fracture," she said. "Approximately 13 percent to 15 percent of older women in the health plan were Asian compared to 27 percent of our study population, which suggests that Asians may be more likely to begin bisphosphonate treatment for primary prevention.”

Learn more about BPs:

Source: Endocrine Society

About the Author
Master's (MA/MS/Other)
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
DEC 03, 2022
Neuroscience
Promising Epilepsy Treatment Suppresses Neuroinflammation
Promising Epilepsy Treatment Suppresses Neuroinflammation
A team of City University of Hong Kong (CityU) neuroscientists recently identified and developed a new drug candidate fo ...
DEC 06, 2022
Drug Discovery & Development
The most expensive drug in the world, Hemgenix, approved at $3.5 million per dose
The most expensive drug in the world, Hemgenix, approved at $3.5 million per dose
On Tuesday, November 22nd, 2022, the United States Food and Drug Administration approved Hemgenix, a new drug to treat h ...
JAN 04, 2023
Health & Medicine
ACER-001- New Drug to Treat Genetic Disorder
ACER-001- New Drug to Treat Genetic Disorder
Urea cycle disorders (UCDs) are genetic conditions most commonly diagnosed in children that result in the body&rsqu ...
JAN 05, 2023
Cannabis Sciences
The New Medical Marijuana and Cannabidiol Research Expansion Act
The New Medical Marijuana and Cannabidiol Research Expansion Act
New legislation is going to open up opportunities to research cannabis and its potential health benefits. Here are the d ...
JAN 29, 2023
Drug Discovery & Development
Introducing a plant toxin that can be used as an antibiotic: albicidin
Introducing a plant toxin that can be used as an antibiotic: albicidin
Albicidin is a peptide antibiotic that works as a DNA gyrase inhibitor with bactericidal activity towards fluoroquinolon ...
FEB 07, 2023
Health & Medicine
ALS Breakthrough: Two Targets Touted to Treat TDP-43 Trafficking Trouble
ALS Breakthrough: Two Targets Touted to Treat TDP-43 Trafficking Trouble
One lab drops two papers touting the clearance of protein aggregation in ALS
Loading Comments...